Australia's most trusted
source of pharma news
Posted 11 December 2025 AM
Fresh from winning the bidding war for Metsera, Pfizer has made another move into the obesity market, signing a collaboration and licence agreement for a GLP-1 pill being developed by YaoPharma.
Pfizer will pay US$150 million up front and as much as US$1.94 billion in developmental, regulatory and commercial milestone payments for the small-molecule GLP-1 receptor agonist YP05002, it announced on Tuesday. YaoPharma will also be eligible for royalties if the drug reaches the market.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.